1. Home
  2. WAL vs TGTX Comparison

WAL vs TGTX Comparison

Compare WAL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Alliance Bancorporation (DE)

WAL

Western Alliance Bancorporation (DE)

N/A

Current Price

$68.46

Market Cap

8.3B

Sector

Finance

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$63.57

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WAL
TGTX
Founded
1994
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
8.5B
IPO Year
2005
2008

Fundamental Metrics

Financial Performance
Metric
WAL
TGTX
Price
$68.46
$63.57
Analyst Decision
Buy
Buy
Analyst Count
15
8
Target Price
★ $89.50
$69.43
AVG Volume (30 Days)
802.6K
★ 1.9M
Earning Date
10-19-2026
11-09-2026
Dividend Yield
★ 2.64%
N/A
EPS Growth
23.13
★ 1746.67
EPS
★ 6.43
0.52
Revenue
★ $135,800,000.00
$2,785,000.00
Revenue This Year
$12.69
$61.95
Revenue Next Year
$4.25
$35.55
P/E Ratio
★ $10.83
$124.71
Revenue Growth
★ 99.71
N/A
52 Week Low
$65.82
$26.76
52 Week High
$97.23
$68.03

Technical Indicators

Market Signals
Indicator
WAL
TGTX
Relative Strength Index (RSI) 30.96 57.99
Support Level $65.82 $52.12
Resistance Level $81.73 $68.03
Average True Range (ATR) 2.23 3.49
MACD -0.85 0.09
Stochastic Oscillator 1.05 67.11

Price Performance

Historical Comparison
WAL
TGTX

About WAL Western Alliance Bancorporation (DE)

Western Alliance Bancorp provides a full spectrum of customized loan, deposit, and treasury management capabilities, including funds transfer and other digital payment offerings. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: